Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

108 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sex Differences in Characteristics, Resource Utilization, and Outcomes of Cardiogenic Shock: Data From the Critical Care Cardiology Trials Network (CCCTN) Registry.
Daniels LB, Phreaner N, Berg DD, Bohula EA, Chaudhry SP, Fordyce CB, Goldfarb MJ, Katz JN, Kenigsberg BB, Lawler PR, Martillo Correa MA, Papolos AI, Roswell RO, Sinha SS, van Diepen S, Park JG, Morrow DA; Critical Care Cardiology Trials Network Investigators. Daniels LB, et al. Among authors: bohula ea. Circ Cardiovasc Qual Outcomes. 2024 Aug;17(8):e010614. doi: 10.1161/CIRCOUTCOMES.123.010614. Epub 2024 Jun 20. Circ Cardiovasc Qual Outcomes. 2024. PMID: 38899459
How does the TRS 2°P score relate to real-world patients?
Bonaca MP, De Ferrari GM, Atar D, Bash LD, Lautsch D, Bohula EA, Horack M, Brudi P, Ferrieres J, Gitt AK. Bonaca MP, et al. Among authors: bohula ea. Eur Heart J Cardiovasc Pharmacother. 2018 Apr 1;4(2):72-74. doi: 10.1093/ehjcvp/pvy004. Eur Heart J Cardiovasc Pharmacother. 2018. PMID: 29554293 Free PMC article. No abstract available.
Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack: Results from TRA 2°P-TIMI 50.
Bohula EA, Aylward PE, Bonaca MP, Corbalan RL, Kiss RG, Murphy SA, Scirica BM, White H, Braunwald E, Morrow DA. Bohula EA, et al. Circulation. 2015 Nov 17;132(20):1871-9. doi: 10.1161/CIRCULATIONAHA.114.015042. Epub 2015 Sep 3. Circulation. 2015. PMID: 26338971 Clinical Trial.
Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction.
Bohula EA, Bonaca MP, Braunwald E, Aylward PE, Corbalan R, De Ferrari GM, He P, Lewis BS, Merlini PA, Murphy SA, Sabatine MS, Scirica BM, Morrow DA. Bohula EA, et al. Circulation. 2016 Jul 26;134(4):304-13. doi: 10.1161/CIRCULATIONAHA.115.019861. Circulation. 2016. PMID: 27440003 Clinical Trial.
Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention.
Bohula EA, Morrow DA, Giugliano RP, Blazing MA, He P, Park JG, Murphy SA, White JA, Kesaniemi YA, Pedersen TR, Brady AJ, Mitchel Y, Cannon CP, Braunwald E. Bohula EA, et al. J Am Coll Cardiol. 2017 Feb 28;69(8):911-921. doi: 10.1016/j.jacc.2016.11.070. J Am Coll Cardiol. 2017. PMID: 28231942 Free article.
Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
Bohula EA, Wiviott SD, Giugliano RP, Blazing MA, Park JG, Murphy SA, White JA, Mach F, Van de Werf F, Dalby AJ, White HD, Tershakovec AM, Cannon CP, Braunwald E. Bohula EA, et al. Circulation. 2017 Dec 19;136(25):2440-2450. doi: 10.1161/CIRCULATIONAHA.117.029095. Epub 2017 Sep 30. Circulation. 2017. PMID: 28972004 Clinical Trial.
108 results